GlassScriptPhysician profile
Alicia D Shelly
NPI 1992022719
$203,077.80
in general payments reported to CMS, 2019-2025
39 companies · $86K in 2025
The $86K reported for 2025 was more than what 97% of Obesity Medicine (Internal Medicine) providers received nationally (typical 2025 total: $202).
See the full distribution for Obesity Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $497 · 2021: $670 · 2022: $893 · 2023: $12K · 2024: $102K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Travel and Lodging: $24K · Consulting Fee: $16K · Food and Beverage: $6,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,525.00 |
| Travel and Lodging | $24,197.23 |
| Consulting Fee | $15,540.00 |
| Food and Beverage | $6,038.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185,230.12 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $13,465.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $488.07 | 2019-2025 | Farxiga |
| Abbvie INC. | $414.56 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.73 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $349.68 | 2020-2025 | Freestyle Libre 3 |
| Amgen INC. | $331.99 | 2020-2025 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $290.72 | 2019-2023 | |
| Glaxosmithkline, LLC. | $282.33 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $177.30 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $168.65 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $161.89 | 2019-2024 | |
| Dexcom, INC. | $126.18 | 2022-2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $121.43 | 2024 | Zurzuvae |
| Vivus LLC | $120.29 | 2025 | Qsymia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Shelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.